Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study.
@article{Mockenhaupt2008StevensJohnsonSA, title={Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study.}, author={Maja Mockenhaupt and Cecile G. Viboud and Ariane Dunant and Luigi Naldi and Sima Halevy and J.N. Bouwes Bavinck and Alexis Sidoroff and J{\"u}rgen Schneck and Jean Claude Roujeau and Antoine Flahault}, journal={The Journal of investigative dermatology}, year={2008}, volume={128 1}, pages={ 35-44 } }
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but severe cutaneous adverse reactions (SCAR) related to a variety of medications. They have a significant public health impact because of high mortality and morbidity. A multinational case-control study conducted in Europe between 1997 and 2001 evaluated the risk of medications to induce SCAR. Cases were actively detected through a hospital network covering more than 100 million inhabitants. Three hospitalized…
797 Citations
Stevens-Johnson syndrome and toxic epidermal necrolysis: a cross-sectional analysis of patients in an integrated allergy repository of a large health care system.
- MedicineThe journal of allergy and clinical immunology. In practice
- 2015
Is acetaminophen associated with a risk of Stevens–Johnson syndrome and toxic epidermal necrolysis? Analysis of the French Pharmacovigilance Database
- MedicineBritish journal of clinical pharmacology
- 2018
Analysis of the French pharmacovigilance data using the ALDEN algorithm found no obvious SJS/TEN risk related to the use of acetaminophen in this large national series.
Medications as Risk Factors of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children: A Pooled Analysis
- MedicinePediatrics
- 2009
It is suspected that acetaminophen (paracetamol) use increases the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis among more unexpected risk factors.
The Medication Risk of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in Asians: The Major Drug Causality and Comparison With the US FDA Label
- MedicineClinical pharmacology and therapeutics
- 2019
Only one acetaminophen‐induced SJS was identified, while several medications labeled as carrying a risk of SJS/TEN by the FDA were not found to have caused any of the cases in the Asian countries investigated in this study.
Assessment of Treatment Approaches and Outcomes in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Insights From a Pan-European Multicenter Study.
- MedicineJAMA dermatology
- 2021
This retrospective pan-European multicenter cohort study noted differences in treatment strategies for SJS/TEN in Europe; the findings suggest the need for prospective therapeutic studies to be conducted and registries to be developed.
Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis: Are Drug Dictionaries Correctly Informing Physicians Regarding the Risk?
- MedicineDrug Safety
- 2013
Information on the risk of SJS/TEN in drug dictionaries needs improvement to enhance the quality of advice given by general physicians and to raise the understanding of risk by patients.
Stevens-Johnson syndrome and toxic epidermal necrolysis: the Food and Drug Administration adverse event reporting system, 2004-2013.
- MedicineAllergology international : official journal of the Japanese Society of Allergology
- 2015
Severe cutaneous adverse drug reactions manifesting as Stevens-Johnson syndrome and toxic epidermal necrolysis reported to the national pharmacovigilance center in Nigeria: a database review from 2004 to 2017
- MedicineTherapeutic advances in drug safety
- 2020
Antiretrovirals, followed by antibiotics, were the most common drug classes reported to cause Stevens-Johnson syndrome and toxic epidermal necrolysis cases in Nigeria, indicating that drug surveillance and counseling in these groups of patients may be beneficial.
Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel.
- MedicineJournal of the American Academy of Dermatology
- 2008
Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with anticonvulsants in a Japanese population: Matched case-control and cohort studies.
- MedicineAllergology international : official journal of the Japanese Society of Allergology
- 2021
References
SHOWING 1-10 OF 27 REFERENCES
The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective.
- MedicineThe Journal of rheumatology
- 2003
Although the absolute risks of SJS and TEN associated with NSAID use are low, these risks should be considered in monitoring patients who recently began therapy and some NSAID not widely used in Europe may have risks comparable to the oxicams.
Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions.
- MedicineLancet
- 1999
SJS and TEN are associated with short-term therapy with phenytoin, phenobarbital, and carbamazepine, and the association with valproic acid seems to be confounded by concomitant short- term therapy with other causal drugs.
Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.
- MedicineThe New England journal of medicine
- 1995
Risk of Stevens–Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics
- MedicineNeurology
- 2005
The risk of hospitalization for Stevens–Johnson syndrome or toxic epidermal necrolysis in new users is low for carbamazepine, lamotrigine, phenytoin, phenobarbital, and valproic acid.
Nevirapine and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis
- MedicineAIDS
- 2001
In European countries the risk of SJS or TEN in the context of HIV infection appears to be associated with nevirapine, and it is suggested discontinuation of the drug as soon as any eruption occurs.
An international collaborative case-control study of severe cutaneous adverse reactions (SCAR). Design and methods.
- MedicineJournal of clinical epidemiology
- 1995
Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study.
- MedicineArchives of dermatology
- 2002
This large prospective study confirmed that erythema multiforme majus differs from Stevens-Johnson syndrome and toxic epidermal necrolysis not only in severity but also in several demographic characteristics and causes.
Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry.
- MedicineJournal of clinical epidemiology
- 1996
Stevens-Johnson syndrome after sertraline.
- MedicineActa dermato-venereologica
- 1999
A patient who developed StevensJohnson syndrome (SJS) after starting treatment with sertraline (Zoloft1) is reported here, believed to be the ®rst case of SJS observed with sERTraline treatment.